Advances in liquid biopsy for bone and soft-tissue sarcomas
International Journal of Clinical Oncology · 2025-09 · 30 (9) · 1722-1733
DOI: 10.1007/s10147-025-02813-2 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Clinical Oncology, online erschienen am 18.07.2025. Verfasst von Yilang Wang und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Orthopaedic Surgery, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama, Japan. Hauptthemen laut MEDLINE: Sarcoma, Bone Neoplasms, Biomarkers, Tumor, Soft Tissue Neoplasms. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 75 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Japan Society for the Promotion of Science London, Okayama University.
Abstract (Originalsprache)
Bone and soft-tissue sarcomas are a heterogeneous group of malignant tumors originating from mesenchymal tissues, accounting for approximately 1% of adult solid malignancies and 20% of pediatric solid malignancies. While blood-based tumor markers are available in major types of cancers, evidence demonstrating useful circulating biomarkers is limited in bone and soft-tissue sarcomas. Despite the development of combined modality treatments, a significant proportion of sarcoma patients respond poorly to chemotherapy or radiotherapy, leading to local relapse or distant metastasis. However, imaging methods, such as X-ray, computed tomography, positron emission tomography, magnetic resonance imaging, and scintigraphy, are mostly used to detect or monitor tumor development. Liquid biopsy is an emerging minimally invasive diagnostic technique that detects tumor-derived molecules in body fluids, including circulating tumor cells, circulating tumor DNA (ctDNA), circulating tumor RNA (ctRNA), and circulating extracellular vesicles. This method offers new possibilities for early tumor detection, prognostic evaluation, and therapeutic monitoring and may serve as a benchmark for treatment modification. This review focuses on the current technological advances in liquid biopsy for bone and soft-tissue sarcoma and explores its potential role in guiding personalized treatments. If these modalities could determine resistance to ongoing therapy or the presence of minimal residual disease at the end of the treatment protocol, the obtained data would be important for determining whether to change treatment approaches or add adjuvant therapies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Orthopaedic Surgery, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama, Japan.
- Department of Orthopaedic Surgery, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama, Japan. tomomedvn@okayama-u.ac.jp.
Förderung
- Japan Society for the Promotion of Science London
- Okayama University
Zitieren
APA
Wang, Y., Fujiwara, T., Kurozumi, T., Ando, T., Ishimaru, T., Kondo, H., Nakata, E., Kunisada, T., & Ozaki, T. (2025). Advances in liquid biopsy for bone and soft-tissue sarcomas. International Journal of Clinical Oncology, 30(9), 1722-1733. https://doi.org/10.1007/s10147-025-02813-2
Vancouver
Wang Y, Fujiwara T, Kurozumi T, Ando T, Ishimaru T, Kondo H, et al. Advances in liquid biopsy for bone and soft-tissue sarcomas. International Journal of Clinical Oncology. 2025;30(9):1722-1733. doi:10.1007/s10147-025-02813-2
BibTeX
@article{Wang2025,
author = {Wang, Yilang and Fujiwara, Tomohiro and Kurozumi, Takanao and Ando, Teruhiko and Ishimaru, Takahiko and Kondo, Hiroya and Nakata, Eiji and Kunisada, Toshiyuki and Ozaki, Toshifumi},
title = {Advances in liquid biopsy for bone and soft-tissue sarcomas},
journal = {International Journal of Clinical Oncology},
year = {2025},
volume = {30},
number = {9},
pages = {1722--1733},
doi = {10.1007/s10147-025-02813-2}
}
EUVIMED